Hosted on MSN1mon
Sionna Therapeutics prices upsized IPO at $18 per share
Clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis—Sionna Therapeutics (SION) priced its upsized initial public offering of ...
조선일보23d
New Paradigm invests 6 billion won in 14 startups, targets 90 billion won in 2025
Courtesy of New Paradigm Following BlueMTec, a representative nurturing corporation that successfully went public (IPO) at the end of 2023, Medical AI, invested in by the 1st fund, has selected ...
Nasdaq1mon
Sionna Therapeutics, Inc. Completes Upsized IPO Raising Approximately $219.2 Million to Advance Cystic Fibrosis Treatments
The IPO's registration statement was declared effective ... company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that ...